drugset
drugset / Trial / NCT06137755

Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above

NCT06137755 ↗

Phase 1 Recruiting 32 enrolled CHA Vaccine Institute Co., Ltd.
Non-randomizedSequentialOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-VZV-001.

Timeline

Start
2023-03-15
Primary completion
2025-03-21
Completion
2025-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject CVI-VZV-001 Vaccine 0.37 ml Intramuscular
Subject CVI-VZV-001 Vaccine 0.5 ml Intramuscular
Subject CVI-VZV-001 Vaccine 0.75 ml Intramuscular
Comparator VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E Vaccine 0.5 ml Intramuscular

Indications

herpes zoster